

Supplementary Online Content

Chu L, Acosta AM, Aazami H, et al. Efficacy and safety of ciprofloxacin plus fluocinolone acetonide among patients with acute otitis externa: a randomized clinical trial. *JAMA Netw Open*. 2022;5(7):e2221699. doi:10.1001/jamanetworkopen.2022.21699

eTable. Clinical Signs and Symptoms at Visit 3 in the MITT Population

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Clinical Signs and Symptoms at Visit 3 in the MITT Population

	CIPRO+FLUO N = 103	CIPRO N = 91	FLUO N = 45
Otorrhea			
Resolved	93 (90.3)	73 (80.2)	38 (84.4)
Not Resolved	10 (9.7)	18 (19.8)	7 (15.6)
Difference in response rate (95% CI) ^a		10.1 (0.1, 20.1)	5.8 (-6.2, 17.9)
P-value ^b		0.046	0.305
Otalgia			
Resolved	81 (78.6)	61 (67.0)	25 (55.6)
Not Resolved	22 (21.4)	30 (33.0)	20 (44.4)
Difference in response rate (95% CI) ^a		11.6 (-0.9, 24.1)	23.1 (6.5, 39.6)
P-value ^b		0.069	0.004
Edema			
Resolved	70 (68.0)	57 (62.6)	26 (57.8)
Not Resolved	33 (32.0)	34 (37.4)	19 (42.2)
Difference in response rate (95% CI) ^a		5.3 (-8.1, 18.7)	10.2 (-6.8, 27.2)
P-value ^b		0.436	0.233

CI, confidence interval; CIPRO+FLUO, ciprofloxacin plus fluocinolone acetonide, CIPRO, ciprofloxacin alone; FLUO, fluocinolone acetonide alone; MITT, microbiological intent-to-treat.

^aDifference is calculated as response rate for combined treatment - response rate for individual component.

^bP-values are calculated using Pearson's Chi Squared test for independence between the combined treatment and each individual component.